#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Diabetes

We recommend klinickastudie

How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

5. 12. 2023 Source: Diabetes

Modern antidiabetics – gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) – significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio- and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been…

srdce

The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease

Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i,…
5. 12. 2023 Source: Diabetes
ledviny

Benefit of Empagliflozin in Patients with Chronic Kidney Disease – Results of the EMPA-KIDNEY Study

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type…
18. 10. 2023 Source: Diabetes

Articles on this topic
lecba a cile diabetu

How to Set Individual Treatment Goals for Type 2 Diabetes?

Treatment goals for type 2 diabetes should always be set individually. In practice, this…
28. 8. 2020 Source: Diabetes
Covid_virus_krev

DPP-4 Inhibitors May Prevent SARS-CoV-2 Entry into Cells

Since the new type of coronavirus SARS-CoV-2 utilizes the DPP-4 receptor to enter human cells,…
3. 8. 2020 Source: Diabetes
rozhodnutí_možnosti_vs._nohy_boty_cesta_volba

Algorithm for Choosing Antidiabetics in Patients with Type 2 Diabetes

As of June 1, 2020, general practitioners can prescribe antidiabetics from the group of…
29. 7. 2020 Source: Diabetes
z UL

How to Improve Diabetic Adherence?

The dream of every doctor is a conscientious patient who follows the prescribed treatment and reports...
7. 5. 2020 Source: Diabetes

Impact of Empagliflozin on the Risk of Cardiovascular Death and Need for Hospitalization Due to Heart Failure

In the EMPA-REG OUTCOME study, empagliflozin reduced the risk of cardiovascular death and the number...
10. 4. 2020 Source: Diabetes

Mechanisms Connecting Diabetes Mellitus and Obesity

Obesity has a close relationship with insulin resistance and diabetes mellitus (DM); weight gain...
29. 3. 2020 Source: Diabetes

Combination of SGLT2 inhibitors with metformin in terms of mechanism of action

In the treatment of type 2 diabetes (T2D), metformin is recommended as the first-line drug alongside...
18. 3. 2020 Source: Diabetes

Favorable effect of linagliptin on renal endothelial functions in patients with type 2 diabetes mellitus

Diabetic nephropathy is the cause of up to 50% of cases of end-stage chronic kidney disease. The...
1. 3. 2020 Source: Diabetes

Regular Walking as an Intervention to Support the Quality of Life of Diabetics

Diabetes mellitus (DM), as a chronic and in many cases disabling disease, limits patients in various...
25. 2. 2020 Source: Diabetes
z UL

Documented Cardiovascular Benefit of Empagliflozin in New American Diabetes Treatment Guidelines

Two leading overseas medical professional societies, the American Diabetes Association (ADA) and...
14. 2. 2020 Source: Diabetes

1 2 3 4 5
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#